ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

S-1 After Surgery Improves Survival, Japanese Trial Finds

February 23, 2007

Stem Cell Transplant More Effective than Chemotherapy

April 25, 2003

PhRMA’s New Ethics Code Prohibits Trinkets, Dinners; Speaking Fees Still OK.

July 11, 2008

Health Groups Urge FDA To Regulate Tobacco Products, Including E-Cigarettes

September 5, 2014

NCI: The Times Have Been “Confusing,” Acting NCI Director Niederhuber Admits in Memo.

June 9, 2006

In Brief: St. Jude To Stay In Memphis; Katterhagens Move To Illinois; ACCC, Nixon In DC Next Week

March 28, 1986